Group 1 - Dingyang Technology has launched the SPB3000X series source load simulator, which includes three models: SPB3100X, SPB3200X, and SPB3300X, featuring high precision, low ripple noise, and fast transient response [1] - Ningbo Huaxiang plans to acquire 40% of Fengmei Power's equity from SAIC Volkswagen, with the total acquisition involving 100% equity [2] - ST Jiaotou will implement a capital reserve conversion to increase share capital, with a total of 267 million shares to be converted [3] Group 2 - Century Huatong's subsidiary Guosheng Capital holds 19.5887 million shares of Moer Thread, accounting for 4.8968% of the total share capital before the IPO [4] - Meidike intends to introduce strategic investors to its subsidiary, with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [5] - Baiyun Airport reported a 12.58% year-on-year increase in passenger throughput in November, totaling 7.3228 million passengers [6] Group 3 - Shengda Resources' subsidiary Honglin Mining has received approval for a three-month extension for trial production [7] - ST Yigou's subsidiary Suning International is expected to increase net profit by approximately 992 million yuan from the sale of eight subsidiaries [8][9] - Huayi Brothers reported overdue debts totaling 52.5 million yuan, exceeding 10% of its audited net assets for 2024 [10] Group 4 - Wanshun New Materials plans to acquire 100% of Eurofoil Luxembourg for 12.3889 million euros, enhancing its aluminum foil production capabilities [11] - Wuhan Tianyuan's subsidiary plans to invest approximately 600 million yuan in two energy storage projects [12] - Maike Biological's subsidiary has received a product registration certificate for a new automatic cell morphology analyzer [13] Group 5 - CATL intends to register for the issuance of bonds not exceeding 10 billion yuan, primarily for project construction and working capital [14] - Yuntianhua plans to acquire 100% of Tianyao Chemical for 36.8858 million yuan, enhancing its fine phosphorus chemical product line [15] - Fucheng Technology's controlling shareholder has reduced its stake by 1.0429 million shares [16] Group 6 - Zhili Fang plans to reduce its stake by up to 1.2% of the company's total shares [17][18] - Qianzhao Optoelectronics' chairman intends to reduce his stake by up to 0.02% [19] - Sanmu Group's subsidiary plans to sell 75 office properties for 24.1068 million yuan [20] Group 7 - Zhuangyuan Pasture's director plans to reduce his stake by up to 3% of the company's total shares [21] - Chongqing Pharmaceutical's subsidiary has signed a licensing agreement with Pfizer, potentially earning up to 50 million USD in milestone payments [22] - Yongqing Environmental Protection's shareholder plans to reduce its stake by up to 1% [23] Group 8 - Lens Technology plans to acquire 100% of PMG International Co., Ltd., enhancing its capabilities in server cabinet business [24] - Xinbang Pharmaceutical is facing prosecution for alleged unit bribery, but its control remains unchanged [25] - Meian Health's shareholders plan to reduce their stake by up to 3% of the company's total shares [26] Group 9 - Central Plaza's subsidiary has decided to suspend operations due to ongoing operational difficulties [27] - Dawn Co. plans to acquire 80% of Ningbo Aisikai for 516 million yuan, including the transfer of related patents and technologies [28] - Kweichow Moutai will distribute over 30 billion yuan in cash dividends based on its 2025 mid-term profit distribution plan [29] Group 10 - Baiyun Airport has received approval from the CSRC for a stock issuance to specific targets [29] - Zai Sheng Technology reported that revenue from aerospace-related products will account for less than 0.5% of its total revenue in 2024 [30]

股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 格隆汇12月10日丨迈克生物(300463.SZ)公布，全资子公司迈克医疗电子有限公司于近日收到四川药品 监督管理局颁发的《医疗器械注册证》，产品名称：全自动细胞形态学分析仪。本次获得注册证的是公 司血球平台的新仪器产品全自动细胞形态学分析仪M100，该产品获证进一步完善了公司血球平台产品 系列化程度，可满足不同客户群体以及不同应用场景的需求，巩固公司在血液诊断领域以及智慧化实验 室领域的竞争优势。同时，公司综合竞争力与市场拓展能力也将得到提升，对公司未来的经营将产生积 极影响。 ...

迈克生物（300463）(300463.SZ)公告，公司全资子公司迈克医疗电子有限公司于近日收到四川药品监 督管理局颁发的《医疗器械注册证》，产品名称为：全自动细胞形态学分析仪。 ...

智通财经APP讯，迈克生物(300463.SZ)公告，公司全资子公司迈克医疗电子有限公司于近日收到四川药 品监督管理局颁发的《医疗器械注册证》，产品名称为：全自动细胞形态学分析仪。 ...

人民财讯12月10日电，迈克生物（300463）12月10日公告，公司全资子公司迈克医疗电子有限公司于近 日收到四川药品监督管理局颁发的《医疗器械注册证》，本次获得注册证的是公司血球平台的新仪器产 品全自动细胞形态学分析仪M100。 ...

证券代码:300463 证券简称:迈克生物 公告编号:2025-107 一、产品注册证具体情况 | 产品名称 | 注册证书 编号 | 注册 类别 | 注册证有效期 | | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 产品用于对外周血涂片血细胞的形态 | | 全自动细胞形 | 川械注准 | Ⅱ | 年 2025 8 | 12 | 月 | 日至 | 图像摄取、可视化观察及描述，包括 | | 态学分析仪 | 20252220266 | | 年 7 | 2030 12 | 月 | 日 | 白细胞单细胞图像摄取、初步分类， | | | | | | | | | 红细胞形态描述及血小板数目估算。 | 二、对公司的影响 迈克生物股份有限公司 关于全资子公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）全资子公司迈克医疗电子有限公司于近日收 到四川药品监督管理局颁发的《医疗器械注册证》，具体情况如下： ...

Core Insights - The company has introduced a humanoid intelligent robot named MICO (My Intelligent Cooperator), which represents an innovative exploration in laboratory automation and intelligence [1] - MICO is currently in the early stages of research and development, focusing on validation and scenario adaptation [1] - The future goal is for intelligent robots to enter laboratories and take over more complex and precise tasks [1]

Core Viewpoint - The company is innovating in the field of laboratory automation and intelligence with its humanoid intelligent robot, MICO, which is currently in the early stages of research and development [1] Group 1: Product Development - The humanoid intelligent robot, MICO, is a form of the company's intelligent laboratory partner [1] - MICO aims to explore future solutions for smart laboratories [1] - The product is still in the initial phase of research validation and scenario adaptation [1] Group 2: Future Applications - The intelligent robot is expected to enter laboratories in the future to take over more complex and precise tasks [1]

| 交易日 | (路) 田樹宗族論 | | 融券会重(股) | 融券余额(元) | | --- | --- | --- | --- | --- | | 2025-12-05 | | 2900.0 | 9.79万 | 112.39万 | | 2025-12-04 | | -1.72万 | 9.50万 | 108.20万 | | 2025-12-03 | | 2300.0 | 11.22万 | 128.24万 | | 2025-12-02 | | 3000.0 | 10.99万 | 126.39万 | | 2025-12-01 | | -5200.0 | 10.69万 | 123.36万 | 证券之星消息，12月5日，迈克生物（300463）融资买入642.24万元，融资偿还486.65万元，融资净买入 155.6万元，融资余额3.16亿元，近3个交易日已连续净买入累计626.08万元。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-12-05 | 155.60万 | 3.16亿 | 5.60% | | 2025-12 ...

Core Insights - The "2025 Chengdu High-tech Zone IVD Industry Supply and Demand Seminar" was held in Chengdu, attracting over 200 participants from leading IVD companies, top academicians, and experts from major hospitals in the Sichuan-Chongqing region, aiming to create a collaborative platform for the IVD industry [1] Group 1: Event Overview - The seminar focused on the theme "Connecting Sichuan and Chongqing, Innovating the Future," aiming to integrate resources across various sectors including government, industry, academia, research, finance, and healthcare [1] - Key activities included policy interpretation, sharing of cutting-edge technologies, supply-demand matching, and project signing, all aimed at fostering high-quality development of the biomedicine industry in the Chengdu-Chongqing economic circle [1] Group 2: Industry Opportunities - Six leading IVD companies from the Sichuan-Chongqing region released an "Opportunity List," covering areas such as IVD reagent R&D, smart manufacturing equipment procurement, and clinical collaborations, with a total value exceeding 10 billion [1] - Collaborative projects were launched between institutions like the Sichuan Academy of Medical Sciences and Chengdu Medical College, focusing on technical challenges and joint talent cultivation [2] Group 3: Collaborative Agreements - Several companies signed "medical-engineering crossover" cooperation agreements, including Chengdu Danodi Medical Technology Co., Ltd. and Chengdu Medical College, focusing on IVD talent training and AI technology development [2] - The event emphasized the integration of AI in IVD, showcasing practical applications in diagnostic reagent development and clinical testing efficiency [2] Group 4: Industry Insights and Discussions - The seminar featured thematic discussions and roundtable forums, addressing topics such as integrated regulatory models for medical device reviews, IVD ecosystem construction from a medical perspective, and international opportunities and challenges [3] - Representatives from various sectors provided insights on regulatory collaboration, industry experience, clinical value, result transformation, financial support, and international pathways for the high-quality development of the Sichuan-Chongqing IVD industry [3]